For a while now there has seemed a disconnect between the progress that Sherri had made with the ‘super compound’ (now historic) her osmium creations in general and the feed of such treasures into the Theralase pipeline. Instead TLT concentrate solely on Rutherrin - which they themselves developed from Sherri`s TLD-1433 6 or so years` ago - in their efforts to deliver the destruction of deep-seated cancers.
Could it be (pure speculation) that while TLT have the exclusive rights to Sherri`s metal-based compounds (and can stop anyone else in North America from exploiting the generic) the US Government is entitled to dictate terms to TLT in respect of research undertaken by Sherri while she has worked/works in their Academic institutions and is driving such a hard bargain that it is not worth TLT`s while to proceed with further related product?
If this tech is being parked until TLT`s exclusivity expires it would explain why the Company’s amazing IP has co-existed with a basement share price and glacial progress.
The false start at Roswell and announcement of the Li Kai Shing tie-up feed into long-held suspicions. If they need to refine Rutherrin further (nano-scintillators etc.) might it have to be in Canada and without reference to the great Chemist herself?
Fortunately TLD-1433 was developed before Sherri left Canada and we have Dr.Lilge and his team who will take Rutherrin to the limits of what it can do. Will this include non-invasive cancer destruction? A question for the AGM perhaps.